Form 144 Axsome Therapeutics For: 26 February

Axsome Therapeutics filed a Form 144 with the U.S. Securities and Exchange Commission on February 26, 2026, indicating its intention to sell restricted securities in the public market. The pharmaceutical company, which specializes in developing treatments for central nervous system disorders, submitted the regulatory filing to provide advance notice of potential sales of its restricted shares. Form 144 filings serve as informational documents rather than commitments to sell, allowing investors to monitor potential insider selling activity. The notice comes as Axsome continues its commercialization efforts for its FDA-approved treatments, including Auvelity for major depressive disorder, and advances its pipeline of novel CNS therapeutics. While the specific number of shares and potential offering price were not disclosed in the filing, the document represents a standard regulatory procedure that publicly traded companies may utilize when planning to sell restricted securities that were acquired through private transactions or other non-public means.